Lupin Launches Generic Cancer Treatment Drug In US Market
As per the Iqvia MATdata, Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales of $40.9 million in the US.
(Source: Envato)
Lupin Ltd. launched a generic cancer treatment drug in the US market on Wednesday. The firm launched Doxorubicin Hydrochloride Liposome Injection in single-dose vials in the US drug market.
The drug maker introduced the product after its alliance partner, ForDoz Pharma Corp., USA (ForDoz) received approval from the United States Food and Drug Administration, according to a statement from Lupin.
The company's product is a generic version of Baxter Healthcare Corporation's Doxil which is used for the treatment of ovarian cancer and acquired immune deficiency syndrome -related Kaposi’s Sarcoma, as well as multiple myeloma.
As per the Iqvia MATdata, Doxorubicin Hydrochloride Liposome Injection had an estimated annual sales of $40.9 million in the US.
Shares of Lupin Ltd. ended 0.44% lower at Rs 2,191 apiece on the NSE, compared to a 0.40% advance in the NSE Nifty 50.
(With Inputs From PTI)
